Effect of intravenous iron sucrose on hemoglobin level, when administered in a standard dose, to anemic pregnant women in rural Northern India

Kanshaiym, Sakiyeva; Abdelazim, Ibrahim A.; Starchenko, Tatyana; Mukhambetalyeva, Gulmira

doi:10.4103/jfmpc.jfmpc_438_18

Cited by 4 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reported incidence of anaphylaxis with IS is low (0.002%), and there are no hypersensitivity reactions reported with IS [25]. The multiple infusion sessions are the main disadvantage of IS (200 mg IS in each session every other day) [20][21][22].…”

Section: Discussionmentioning

confidence: 99%

“…The iron deficiency anaemia in pregnant women classified according to World Health Organization into severe anaemia when Hb < 7 g/dl, moderate anaemia when Hb 7–8.9 g/dl, and mild anaemia when Hb 9–10.9 g/dl [ 21 – 22 ].…”

Section: Methodsmentioning

confidence: 99%

“…The iron sucrose (IS) was approved in the USA and Europe for treatment of ID/IDA [ 20 ]; the multiple infusion sessions are the main disadvantage of IS [ 21 , 22 ]. Ferric carboxy maltose (FCM) is a new intravenous (IV) iron that can be used for correction of ID/IDA when oral iron preparations are ineffective, contraindicated, or when there is clinical need to deliver iron for correction of ID/IDA rapidly [ 22 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy of ferric carboxy maltose in treatment of iron deficiency/iron deficiency anaemia during pregnancy

Obaid¹,

Abdelazim²,

Abu-Faza³

et al. 2023

View full text Add to dashboard Cite

Introduction: To evaluate the efficacy of ferric carboxy maltose (FCM) in the treatment of iron deficiency/iron deficiency anaemia (ID/IDA) during pregnancy.Material and methods: Pregnant women ≥ 20 years old diagnosed with ID (serum ferritin < 15 μg/l) and moderate IDA were included in this study for correction of their ID/IDA. The participants received an FCM infusion for correction of their ID/IDA. The pre-treatment ferritin, haemoglobin (Hb), and red blood cell (RBC) indices were compared with the 6-and 12-week post-treatment values to evaluate the efficacy of FCM in the treatment of ID/IDA during pregnancy.Results: The pre-treatment ferritin and Hb significantly increased from 10.3 ±2.3 μg/l and 7.99 ±0.6 g/dl, respectively, to 139.5 ±1.9 and 14.04 ±0.45, respectively, 6-weeks after FCM infusion (p = 0.02 and 0.001, respectively), and to 128.9 ±1.7 and 13.02 ±0.5, respectively, 12-weeks after FCM infusion (p = 0.0008 and 0.02, respectively).In addition, the pre-treatment RBCs mean corpuscular volume and RBCs mean corpuscular haemoglobin (MCH) significantly increased from 72.02 ±3.5 fl and 23.9 ±1.9 pg, respectively, to 90.6 ± 2.8 fl and 29.98 ±1.5 pg, respectively, 6 weeks after FCM infusion (p = 0.01 and p = 0.007, respectively), and to 89.5 ±2.9 fl and 30.2 ±1.5 pg, respectively, 12 weeks after FCM infusion (p = 0.02 and 0.007 respectively).Conclusions: The ferric carboxy maltose was safe and effective for the treatment of ID/IDA during pregnancy within 6 weeks. The serum ferritin and Hb levels and the RBC indices remained significantly high 12 weeks after FCM infusion compared to the pre-treatment values.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of ferric carboxy maltose in treatment of iron deficiency/iron deficiency anaemia during pregnancy

Obaid¹,

Abdelazim²,

Abu-Faza³

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Participants were asked during each antenatal care visit about their compliance to iron tablets, and the side effects related to oral iron as metallic taste, gastrointestinal (GIT) intolerance/upset, and/or constipation. The pre-treatment ferritin, hemoglobin, RBCs-MCV, and RBCs-MCH were compared by the post-treatment values in the two studied groups to detect the effcacy of HIO compared to FF in treatment of IDA during pregnancy as a primary outcome (16)(17)(18)(19).…”

Section: Methodsmentioning

confidence: 99%

Heme-Iron OptiFer® in the Treatment of Iron Deficiency Anemia During Pregnancy

Abdelazim

Abu-Faza

Al-Ajmi

et al. 2021

Gynecol Obstet Reprod Med

View full text Add to dashboard Cite

OBJECTIVES: This study designed to compare the efficacy, and tolerability of heme-iron OptiFer® to ferrous fumarate in the treatment of iron deficiency anemia during pregnancy. STUDY DESIGN: Two hundred and thirty-four (234) women with iron deficiency anemia during pregnancy were included in this study; 121 women in the heme-iron OptiFer® group, and 113 women in the ferrous fumarate group. Women in the heme-iron OptiFer® group received OptiFer® tablets twice daily for ≥3 months then once daily as a maintenance dose. Women in the ferrous fumarate group received 350 mg oral ferrous fumarate once daily for ≥3 months. The pre-treatment ferritin, hemoglobin, red blood cells-mean corpuscular volume, and red blood cells-mean corpuscular hemoglobin were compared by the post-treatment values in the two studies. RESULTS: The post-treatment hemoglobin and ferritin were significantly high in the heme-iron OptiFer® group (11.2±7.1 gm/dL and 112.8±54.8 ug/l, respectively) compared to the ferrous fumarate group (10.9 ±5.1 and 89.9±43.3, respectively; p=0.0002 and p=0.006; respectively). The post-treatment red blood cells-mean corpuscular volume and red blood cells-mean corpuscular hemoglobin were significantly high in the heme-iron OptiFer® group (92.0±4.1 fl and 31.9±6.2 pg, respectively) compared to the ferrous fumarate group (87.7±2.9 and 28.5±4.7, respectively; p=0.0001 and p=0.001, respectively). The rates of poor compliance and gastrointestinal intolerance were significantly high in the ferrous fumarate group compared to the heme-iron OptiFer® group (12.4% and 19.5%, respectively versus 3.3% and 2.5%, respectively), (p=0.01 and p=0.0001, respectively). CONCLUSION: Heme-iron OptiFer® is an effective therapeutic option for the treatment of iron deficiency anemia during pregnancy with low side effects. heme-iron OptiFer® can be used in women who have low compliance, and/or gastrointestinal intolerance to conventional iron salts.

show abstract

Heme-Iron Optifer Versus Intravenous Iron/Ferosac in Treatment of Iron Efficiency Anemia During Pregnancy

Abdelazim

Shikanova

Karimova

et al. 2021

SN Compr. Clin. Med.

View full text Add to dashboard Cite

Effect of intravenous iron sucrose on hemoglobin level, when administered in a standard dose, to anemic pregnant women in rural Northern India

Cited by 4 publications

References 6 publications

Efficacy of ferric carboxy maltose in treatment of iron deficiency/iron deficiency anaemia during pregnancy

Efficacy of ferric carboxy maltose in treatment of iron deficiency/iron deficiency anaemia during pregnancy

Heme-Iron OptiFer® in the Treatment of Iron Deficiency Anemia During Pregnancy

Heme-Iron Optifer Versus Intravenous Iron/Ferosac in Treatment of Iron Efficiency Anemia During Pregnancy

Contact Info

Product

Resources

About